{"id":45382,"date":"2025-10-31T11:35:42","date_gmt":"2025-10-31T03:35:42","guid":{"rendered":"https:\/\/flcube.com\/?p=45382"},"modified":"2025-10-31T11:35:43","modified_gmt":"2025-10-31T03:35:43","slug":"brightgene-submits-hkex-prospectus-aiming-for-main%e2%80%91board-listing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45382","title":{"rendered":"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing"},"content":{"rendered":"\n<p><strong>BrightGene Bio\u2011Medical Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688166<\/a>) filed its prospectus with the <strong>Stock Exchange of Hong\u202fKong Limited (HKEX)<\/strong> today, announcing its intention to list on the <strong>Main Board<\/strong>. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high\u2011need therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-snapshot\"><strong>Company Snapshot<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Ticker<\/strong><\/td><td>688166.SH (China) \/ HKEX filing<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2001<\/td><\/tr><tr><td><strong>Core Competencies<\/strong><\/td><td>Active Pharmaceutical Ingredients (APIs), high\u2011end finished dosage forms (FDFs), and innovative drug development<\/td><\/tr><tr><td><strong>Commercial Portfolio<\/strong><\/td><td>40+ products (12 FDFs, 29 APIs\/intermediates)<\/td><\/tr><tr><td><strong>Key Revenue\u2011Drivers<\/strong><\/td><td>Micafungin Sodium, Oseltamivir Phosphate, Caspofungin Acetate, Anidulafungin, Fidaxomicin, Eribulin Mesylate, Pimecrolimus<\/td><\/tr><tr><td><strong>Innovative Pipeline<\/strong><\/td><td>7 candidates, featuring <strong>BGM0504<\/strong> (GLP\u20111\/GIP dual\u2011agonist for Type\u202f2\u202fDiabetes &amp; obesity)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-hkex\"><strong>Why HKEX?<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Efficiency<\/strong> \u2013 HKEX offers a large, liquid market with a strong appetite for biotech listings.<\/li>\n\n\n\n<li><strong>Strategic Visibility<\/strong> \u2013 Listing in Hong\u202fKong enhances BrightGene\u2019s profile among global investors and partners.<\/li>\n\n\n\n<li><strong>Regulatory Synergy<\/strong> \u2013 The prospectus aligns with HKEX\u2019s stringent disclosure standards, reinforcing investor confidence.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-highlights\"><strong>Pipeline Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BGM0504<\/strong> \u2013 A GLP\u20111\/GIP dual\u2011agonist that has entered Phase\u202fII, poised to become a <strong>Best\u2011in\u2011Class<\/strong> therapy for Type\u202f2\u202fDiabetes and obesity.<\/li>\n\n\n\n<li><strong>Other Candidates<\/strong> \u2013 Six additional molecules across oncology, infectious disease, and metabolic disorders, all supported by robust pre\u2011clinical data.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-outlook\"><strong>Financial Outlook<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Growth<\/strong> \u2013 Over the last fiscal year, BrightGene\u2019s product sales surged 18\u202f%, driven by the expanding market for its antifungal and antiviral APIs.<\/li>\n\n\n\n<li><strong>Capital Allocation<\/strong> \u2013 Proceeds from the HKEX listing will fund clinical development, manufacturing scale\u2011up, and strategic acquisitions.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BrightGene Bio\u2011Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2536,72,1179],"class_list":["post-45382","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-brightgene-bio-medical-technology","tag-ipo","tag-sha-688166"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BrightGene Bio\u2011Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of Hong\u202fKong Limited (HKEX) today, announcing its intention to list on the Main Board. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high\u2011need therapeutic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45382\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing\" \/>\n<meta property=\"og:description\" content=\"BrightGene Bio\u2011Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of Hong\u202fKong Limited (HKEX) today, announcing its intention to list on the Main Board. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high\u2011need therapeutic areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45382\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T03:35:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T03:35:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing\",\"datePublished\":\"2025-10-31T03:35:42+00:00\",\"dateModified\":\"2025-10-31T03:35:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3104.webp\",\"keywords\":[\"BrightGene Bio-Medical Technology\",\"IPO\",\"SHA: 688166\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45382#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45382\",\"name\":\"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3104.webp\",\"datePublished\":\"2025-10-31T03:35:42+00:00\",\"dateModified\":\"2025-10-31T03:35:43+00:00\",\"description\":\"BrightGene Bio\u2011Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of Hong\u202fKong Limited (HKEX) today, announcing its intention to list on the Main Board. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high\u2011need therapeutic areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45382\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3104.webp\",\"width\":1080,\"height\":608,\"caption\":\"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45382#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing - Insight, China&#039;s Pharmaceutical Industry","description":"BrightGene Bio\u2011Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of Hong\u202fKong Limited (HKEX) today, announcing its intention to list on the Main Board. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high\u2011need therapeutic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45382","og_locale":"en_US","og_type":"article","og_title":"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing","og_description":"BrightGene Bio\u2011Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of Hong\u202fKong Limited (HKEX) today, announcing its intention to list on the Main Board. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high\u2011need therapeutic areas.","og_url":"https:\/\/flcube.com\/?p=45382","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T03:35:42+00:00","article_modified_time":"2025-10-31T03:35:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45382#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45382"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing","datePublished":"2025-10-31T03:35:42+00:00","dateModified":"2025-10-31T03:35:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45382"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45382#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3104.webp","keywords":["BrightGene Bio-Medical Technology","IPO","SHA: 688166"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45382#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45382","url":"https:\/\/flcube.com\/?p=45382","name":"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45382#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45382#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3104.webp","datePublished":"2025-10-31T03:35:42+00:00","dateModified":"2025-10-31T03:35:43+00:00","description":"BrightGene Bio\u2011Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of Hong\u202fKong Limited (HKEX) today, announcing its intention to list on the Main Board. The company seeks to raise capital to accelerate its pipeline and expand its global footprint in metabolic, respiratory, and other high\u2011need therapeutic areas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45382#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45382"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45382#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3104.webp","width":1080,"height":608,"caption":"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45382#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BrightGene Submits HKEX Prospectus, Aiming for Main\u2011Board Listing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45382"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45382\/revisions"}],"predecessor-version":[{"id":45384,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45382\/revisions\/45384"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45383"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}